title: Lobe-specific proteome changes in the dorsal-lateral and ventral prostate of TRAMP mice versus wild-type mice.
abstract: The transgenic adenocarcinoma of mouse prostate (TRAMP) is the most widely used transgenic model for prostate cancer chemoprevention studies. Although two lobe-specific lineages of carcinogenesis have been described, the molecular mechanisms are still poorly defined. Here, we concurrently profiled the proteome of dorsal-lateral (DLP) and ventral (VP) prostate lobes of both TRAMP and littermate WT C57BL/6 mice of 18 wk by 2-D LC-MALDI-TOF/TOF with iTRAQ labeling. A total of 483 and 748 proteins were identified at critical false discovery rates of 1 and 5%. In WT mice, 84 proteins were found to have different expression levels between DLP and VP. In TRAMP mice, 118 proteins significantly changed in DLP and/or VP during TRAMP carcinogenesis. Among them, 55 and 36 proteins were uniquely changed in DLP or VP lobe, respectively, and 27 proteins in both DLP and LP lobe. Ingenuity Pathway Analysis was able to segregate proteins changed in two lobes into different pathway networks. In addition to serving as reference for prostate proteomic profiles, our data suggest that different sets of proteins are involved in the carcinogenesis in DLP versus VP in the TRAMP model.
authors: The Hormel Institute, University of Minnesota, Austin, MN, USA. jinhui.zhang@ttuhsc.edu
authors: Jinhui
authors: J
authors: Zhang
authors: Lei
authors: L
authors: Wang
authors: Yong
authors: Y
authors: Zhang
authors: Li
authors: L
authors: Li
authors: Leeann
authors: L
authors: Higgins
authors: Junxuan
authors: J
authors: Lü
references: Cancer Prev Res (Phila). 2009 May;2(5):484-95
references: 19401524
references: Mol Cell Proteomics. 2007 Sep;6(9):1638-55
references: 17533153
references: Mol Cell Endocrinol. 2004 Apr 30;219(1-2):171-80
references: 15149738
references: J Proteome Res. 2009 Jan;8(1):94-103
references: 19012427
references: J Biol Chem. 2005 Oct 28;280(43):36442-51
references: 16055444
references: J Androl. 2009 Nov-Dec;30(6):669-78
references: 19578134
references: Cancer Invest. 2008 Oct;26(8):843-51
references: 18798064
references: Prostate. 2005 Aug 1;64(3):224-39
references: 15712212
references: Cancer Biol Ther. 2007 Jun;6(6):957-64
references: 17548965
references: Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43
references: 7724580
references: Am J Pathol. 2008 Jan;172(1):236-46
references: 18156212
references: Neoplasia. 2009 Oct;11(10):1042-53
references: 19794963
references: Endocr Relat Cancer. 2010 Jan 29;17(1):R1-17
references: 19903745
references: Cancer Res. 2005 Aug 1;65(15):6773-9
references: 16061659
references: Prostate. 2002 Jan 1;50(1):54-63
references: 11757036
references: J Endocrinol. 2006 Sep;190(3):793-803
references: 17003280
references: Prostate. 2000 Mar 1;42(4):274-9
references: 10679756
references: Int J Cancer. 2007 Dec 15;121(12):2596-605
references: 17722004
references: Cancer Prev Res (Phila). 2010 Aug;3(8):994-1006
references: 20647336